As over 50 generic versions of the blockbuster weight-loss drug hit Indian markets on March 21, 2026, a familiar question resurfaces: will affordability come at the cost of safety—and who will doctors trust?
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
